CD20阴性结节性淋巴细胞为主型霍奇金淋巴瘤:三级癌症中心20年连续病例系列
该研究回顾性分析单中心病理档案与病历,在486例可评估CD20的NLPHL患者中识别出14例(2.8%)LP细胞CD20表达缺失,排除既往利妥昔单抗者及临床资料不足者后,6例为未接受利妥昔单抗的CD20阴性NLPHL。所有病例LP细胞均表达B细胞抗原(尤其Oct-2),CD30、CD15及EBER阴性。CD20阴性NLPHL可呈经典型及变异型组织学模式,临床行为谱与NLPHL预期相符,包括1例疑似大细胞转化。
要点
- NLPHL可原发CD20阴性,未接受利妥昔单抗者亦可出现。
- 广泛免疫表型(Oct-2、PAX5、CD79a等)有助与富淋巴细胞经典型霍奇金淋巴瘤鉴别。
- CD20阴性NLPHL组织学模式及临床行为谱与NLPHL预期范围一致。
核心结论
- NLPHL可原发CD20阴性,无需既往利妥昔单抗暴露。
- 此类病例需广泛免疫表型与富淋巴细胞经典型霍奇金淋巴瘤鉴别,二者临床行为和治疗不同。
- 本组CD20阴性NLPHL呈经典型及变异型组织学模式,临床行为谱在NLPHL预期范围内,包括1例疑似大细胞转化。
研究设计与样本
- 单中心回顾性研究,检索病理档案与病历中的CD20阴性NLPHL。
- 486例NLPHL患者有CD20结果可供复习,其中14例(2.8%)LP细胞CD20表达缺失。
- 排除既往利妥昔单抗者7例及临床病史不足者1例,最终分析6例未接受利妥昔单抗的CD20阴性NLPHL。
主要发现
- 6例CD20阴性NLPHL中,所有病例LP细胞均表达B细胞抗原,尤其Oct-2,PAX5和CD79a常也暗淡。
- 所有评估病例CD30、CD15及EBER阴性。
- 2例为高危变异免疫结构模式D。
- 1例为结外病变,累及脾和骨,疑似大细胞转化。
- 5例有随访:4例治疗后完全缓解存活,1例带瘤存活(复发)。
关键数值与推荐
- 486例NLPHL中14例(2.8%)LP细胞CD20表达缺失。
- 排除7例既往利妥昔单抗者和1例临床病史不足者后,分析6例未接受利妥昔单抗的CD20阴性NLPHL。
- 所有病例LP细胞表达B细胞抗原(尤其Oct-2),PAX5和CD79a常暗淡;CD30、CD15、EBER阴性。
临床怎么用
- 对疑似NLPHL但CD20阴性的病例,应加做Oct-2、PAX5、CD79a等B细胞标记及CD30、CD15、EBER以除外富淋巴细胞经典型霍奇金淋巴瘤。
- 需询问利妥昔单抗治疗史,因其可导致CD20表达缺失。
- CD20阴性NLPHL可按NLPHL标准治疗(局部放疗和/或化疗),但需注意变异型模式及疑似转化。
局限性
- 单中心回顾性研究,样本量小(最终分析6例)。
- 部分病例临床资料不足被排除,随访仅5例可用。
- CD20阴性NLPHL的生物学与临床意义需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare, indolent Hodgkin lymphoma subtype with distinct clinicopathologic features and treatment paradigms. The neoplastic lymphocyte-predominant cells typically express bright CD20 and other B-cell antigens, which distinguishes them from Hodgkin/Reed-Sternberg cells of lymphocyte-rich classic Hodgkin lymphoma. OBJECTIVE.—: To characterize the clinicopathologic features of CD20-negative NLPHL at a single institution. DESIGN.—: A retrospective search for CD20-negative NLPHL in our pathology archives and medical records was conducted. RESULTS.—: Of 486 NLPHL patients identified with CD20 available for review, 14 (2.8%) had LP cells with absent CD20 expression. Patients with prior rituximab administration (n = 7) and insufficient clinical history (n = 1) were excluded, leaving 6 patients with rituximab-naïve, CD20-negative NLPHL. A broad immunohistochemical panel showed the LP cells in all cases expressed B-cell antigens, particularly Oct-2, although PAX5 and CD79a were frequently also dim. CD30, CD15, and Epstein-Barr virus-encoded small RNAs were negative in all evaluated cases. Two patients had high-risk variant immunoarchitectural pattern D. One patient had extranodal disease, involving the spleen and bone, and was suspected to have large cell transformation. Standard NLPHL therapy was given, including local radiation and/or chemotherapy. Of 5 patients with available follow-up, 4 are alive in complete remission after therapy, and 1 is alive with relapsed disease. CONCLUSIONS.—: NLPHL can lack CD20 de novo without prior rituximab therapy. In such cases, extensive immunophenotyping helps distinguish NLPHL from lymphocyte-rich classic Hodgkin lymphoma, which differ in clinical behavior and therapy. In our series, CD20-negative NLPHL showed both classic and variant histologic patterns and the expected range of clinical behavior seen in NLPHL, including 1 case with suspected large cell transformation.
引用
- Menke JR, Spinner MA, Natkunam Y, et al. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center. Arch Pathol Lab Med. 2021. PMID: 32991677. doi:10.5858/arpa.2020-0135-OA
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。